Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.75 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.75 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | THPO | P40225 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | APEX1 | P27695 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5717709 | 1.00 | CYP3A4 (0.75) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| SCHEMBL18878769 | 1.00 | CYP3A4 (0.75) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| Hydrochloric Acid SCHEMBL27719660 | 0.98 | CYP3A4 (0.73) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| Histidine SCHEMBL27646598 | 0.94 | CYP3A4 (0.88) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| Histidine SCHEMBL137600 | 0.86 | CYP3A4 (1.00) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| Histidine SCHEMBL19974306 | 0.86 | CYP3A4 (1.00) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| Histidine SCHEMBL3260 | 0.86 | CYP3A4 (1.00) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| Histidine SCHEMBL30852263 | 0.86 | CYP3A4 (1.00) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| D-Histidine SCHEMBL288043 | 0.86 | CYP3A4 (1.00) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| Histidine SCHEMBL388560 | 0.86 | CYP3A4 (1.00) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104995319-B | Valuable metal extracting process | 国立大学法人九州大学 | 2016-10-19 | — | — | CN | claimed |
| CN-105074022-B | Method for separating impurities from an acidic solution containing nickel, cobalt and/or scandium | 国立大学法人九州大学 | 2016-10-19 | — | — | CN | claimed |
| CN-103582711-B | Valuable metal extraction agent and valuable metal extraction method using same | NAT UNIV CORP KYUSHU UNIV | 2015-03-25 | — | — | CN | claimed |
| CN-101563339-A | 2-benzimidazolyl-6-morpholino-4- (azetidine, pyrrolidine, piperidine or aza ) pyrimidine derivatives as P I3K and MtToR inhibitors for the treatment of proliferative diseases | ASTRAZENECA AB (SE) | 2009-10-21 | — | — | CN | claimed |
| CN-101535296-A | 2-benzimidazolyl-6-morpholino-4-phenylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders | ASTRAZENECA AB (SE) | 2009-09-16 | — | — | CN | claimed |
| CN-101460523-A | Bifunctional polysaccharides | ADOCIA (FR) | 2009-06-17 | — | — | CN | claimed |
| CN-101300267-A | Polyglutamic acids functionalised by histidine derivatives and hydrophobic groups and the uses thereof in particular for therapeutic purposes | FLAMEL TECH SA (FR) | 2008-11-05 | — | — | CN | claimed |
| CN-1340054-A | 2-amino-6-anilino-purines and their use as medicaments | NOVARTIS AG (CH) | 2002-03-13 | — | — | CN | claimed |
| CN-1338456-A | Benzodiazepine compound containing imidazole propionamido and preparation method and application thereof | INST OF MEDICAL MATERIALS CHIN (CN) | 2002-03-06 | — | — | CN | claimed |
| CN-1066147-C | Purine derivatives and process for preparing same | 诺瓦提斯公司 | 2001-05-23 | — | — | CN | claimed |
| CN-1202896-A | Purine derivatives and processes for their preparation | 诺瓦提斯公司 | 1998-12-23 | — | — | CN | claimed |
| WO-2022235699-A2 | POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| CN-115066438-A | ASGPR binding compounds for degrading extracellular proteins | 阿维拉治疗公司 | 2022-09-16 | — | — | CN | disclosed |
| US-10851367-B2 | Tissue-specific genome engineering using CRISPR-Cas9 | PFIZER INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20170137801-A1 | TISSUE-SPECIFIC GENOME ENGINEERING USING CRISPR-CAS9 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-05-18 | — | — | US | disclosed |
| CN-1311794-A | Aerothricin analogs, their prepn. and use | HOFFMANN LA ROCHE (CH) | 2001-09-05 | — | — | CN | disclosed |
| CN-1066147-C | Purine derivatives and process for preparing same | 诺瓦提斯公司 | 2001-05-23 | — | — | CN | disclosed |
| CN-1202896-A | Purine derivatives and processes for their preparation | 诺瓦提斯公司 | 1998-12-23 | — | — | CN | disclosed |
| CN-1047075-A | Luminandide medicine | MILLS RANDELL L (US) | 1990-11-21 | — | — | CN | disclosed |
| CN-87100769-A | Have 2-[2-[N, two (2-chloroethyl) the phosphinylidyne diamino oxygen bases of N-] ethyl] novel heterocyclic compound of group | — | 1987-09-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10851367-B2 | Tissue-specific genome engineering using CRISPR-Cas9 | ASGR1, LDLR, HAVCR2 | CYP3A4 3252/4885SLC7A5 3548/4885HRH4 3479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.